文献速递胸部肿瘤

晚期非小细胞肺癌进展后继续EGFR抑制治疗

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2016-11-17

本文综述了EGFR突变晚期非小细胞肺癌患者在一线EGFR酪氨酸激酶抑制剂(TKI)进展后继续抑制EGFR的合理性及策略。文章讨论了系统性进展的管理(继续TKI单药、药物假期、联合化疗或靶向治疗),以及惰性小体积无症状生长(非中枢神经系统寡转移进展)和中枢神经系统寡转移患者的处理,并展望通过下一代测序对连续肿瘤再活检和循环血浆DNA进行个体化精准医学管理。

要点

  • 常规做法是进展后换二线治疗,但对惰性小体积无症状生长者继续TKI日益普遍。
  • 当前疗效评估标准基于影像而未考虑症状获益及分子临床异质性,存在局限。
  • 管理策略包括继续TKI单药、药物假期、联合化疗或靶向治疗,以及针对寡转移的局部处理。

核心结论

  • 对EGFR突变晚期非小细胞肺癌进展后继续EGFR抑制治疗需根据肿瘤生长模式和临床情景个体化决策,未来可借助连续再活检和循环血浆DNA的下一代测序指导精准管理。

研究设计与样本

  • 综述文章,回顾性总结继续EGFR抑制剂 beyond progression 的合理性及不同临床情景下的处理策略。

主要发现

  • 多数EGFR突变非小细胞肺癌患者对一线EGFR-TKI有反应,但几乎均不可避免地获得耐药并出现疾病进展。
  • 继续TKI beyond progression在惰性、小体积无症状生长患者中日益普遍,可能持续获益并避免「撤药性肿瘤 flare」。
  • 当前疗效评估标准基于影像学评估,未考虑症状获益或肿瘤生长与药物反应的复杂分子和临床异质性,存在局限。
  • 管理策略包括继续EGFR-TKI单药、引入药物假期、或联合化疗或其他分子靶向药物。
  • 对非中枢神经系统寡转移进展和中枢神经系统寡转移的EGFR突变非小细胞肺癌患者需分别处理。

临床怎么用

  • 原文未据此给出推荐;综述讨论了在系统性进展时继续EGFR-TKI单药、药物假期或联合治疗等策略,以及针对惰性小体积无症状生长和中枢神经系统寡转移的个体化处理。

局限性

  • 当前疾病反应评估标准基于影像学评估,未考虑症状获益或肿瘤生长与药物反应的复杂分子和临床异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and develop disease progression. Conventional practice would be to switch treatments to second-line therapy. However, continuing TKIs beyond progression is becoming increasingly commonplace in patients with indolent, small volume asymptomatic growth, who may potentially continue to derive ongoing clinical benefit and to avoid a 'withdrawal tumour flare'. Nevertheless, there are limitations to our current criteria for assessing disease response, which are based on radiological assessments without considering symptomatic benefit, or the complex molecular and clinical heterogeneity of tumour growth and drug response patterns. In this article, we review the rationale for continuing EGFR inhibitors in patients with EGFR mutant NSCLC beyond disease progression and discuss strategies that have been pursued in the context of molecularly and clinically heterogeneous populations of tumour growth depending on the different clinical scenarios encountered. We discuss the management of systemic disease progression, including continuing EGFR TKIs alone, introducing a drug holiday, or combining TKIs with chemotherapy or other molecularly targeted agents. We also focus on approaches in managing patients with indolent, small volume asymptomatic growth (non-CNS oligometastatic disease progression) and those with oligometastatic EGFR mutant NSCLC with involvement of the central nervous system. We envision future precision medicine strategies through the use of next generation sequencing strategies of serial tumour rebiopsies and circulating plasma DNA to individualise the management for such patients during disease progression.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yap TA, Macklin-Doherty A, Popat S, et al. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer. 2016. PMID: 27866095. doi:10.1016/j.ejca.2016.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。